Xeris Pharmaceuticals | XERS - Cost Of Sales


Xeris Pharmaceuticals reported $13.71M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Celltrion KRW 402.86B 14.24B Sep/2025
Cspc Pharmaceutical CNY 2.28B 25.27M Sep/2025
Deva Holding AS TRY 991.13M 182.81M Sep/2023
Divis Laboratories Ltd INR 10.63B 1.23B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Kangmei Pharma CNY 1.11B 84.66M Sep/2025
Knight Therapeutics CAD 47.25M 990K Sep/2024
Laboratorios Farma EUR 186.09M 11.06M Dec/2023
Medical Developments International AUD 2.18M 3.09M Jun/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neuren Pharmaceuticals AUD 7.45M 6.56M Jun/2025
Organigram Holdings CAD 77.46M 14.63M Sep/2025
Pacira USD 54.62M 6.02M Dec/2025
Perrigo USD 747.4M 81.2M Dec/2025
Pharma Mar EUR 2.3M 477K Sep/2025
Qiagen NV USD 217.43M 29.65M Dec/2025
Sartorius EUR 450M 18.1M Sep/2025
Sino Biopharmaceutical CNY 3.08B 589.65M Jun/2025
Supernus Pharmaceuticals USD 47.53M 4.24M Dec/2025
Tilray USD 164.37M 8.41M Sep/2025
Zz Pientze Pharmaceu CNY 1.34B 601.08M Sep/2025